At 8.5% CAGR, the Asia Pacific Lung Cancer Screening Market is projected to be worth US$ 1,362.43 million by 2030, says Business Market Insights

According to Business Market Insights research, the Asia Pacific lung cancer screening market was valued at US$ 711.20 million in 2022 and is expected to reach US$ 1,362.43 million by 2030, registering a CAGR of 8.5% from 2022 to 2030. Rising lung cancer incidences and increasing government are the critical factors attributed to the Asia Pacific lung cancer screening market.

Several countries face challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are "BreastScreen," the "National Bowel Cancer Screening Program," and the "National Cervical Screening Program."

On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.

Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer recommends implementing feasibility screening programs in the countries of Asia Pacific without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the lung cancer screening market during the forecast period.

On the contrary, high cost of lung cancer screening hampers the Asia Pacific lung cancer screening market.  

Based on cancer type, the Asia Pacific lung cancer screening market is segmented into non–small cell lung cancer (NSCLC) and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 75.6% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 537.32 million. It is projected to garner US$ 1,012.83 million by 2030 to expand at 8.2% CAGR during 2022–2030.

Based on technology, the Asia Pacific lung cancer screening market is segmented into Chest X-Ray, Low Dose Computed Tomography (LDCT), liquid biopsy, and others. The chest X-Ray segment held 38.9% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 276.82 million. It is projected to garner US$ 528.07 million by 2030 to expand at 8.4% CAGR during 2022–2030.

Based on age group, the Asia Pacific lung cancer screening market is segmented into 50 and Older and Below 50. The 50 and older segment held 89.0% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 632.97 million. It is projected to garner US$ 1,204.30 million by 2030 to expand at 8.4% CAGR during 2022–2030.

Based on end user, the Asia Pacific lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 41.6% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 296.00 million. It is projected to garner US$ 545.92 million by 2030 to expand at 8.0% CAGR during 2022–2030.

Based on country, the Asia Pacific lung cancer screening market has been categorized into the China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that the China captured 83.5% share of Asia Pacific lung cancer screening market in 2022. It was assessed at US$ 593.71 million in 2022 and is likely to hit US$ 1,134.08 million by 2030, exhibiting a CAGR of 8.4% during 2022–2030.

Key players operating in the Asia Pacific lung cancer screening Market are Intelerad Medical Systems, Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, and Siemens AG, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com